Matinas BioPharma Holdings, Inc.

As of May 9, 2024, Matinas BioPharma Holdings, Inc. is considered overvalued and does not qualify for a favorable valuation grade due to significant financial challenges, including a low return on equity of -256.46% and poor performance compared to peers and the S&P 500.

As of June 17, 2025, the technical trend is mildly bullish, supported by positive weekly and monthly MACD and RSI readings, despite some short-term bearish signals from daily moving averages.

As of March 2022, the management team of Matinas BioPharma Holdings, Inc. includes Mr. Herbert Conrad (Independent Chairman), Mr. Jerome Jabbour (CEO), Mr. Patrick LePore (Independent Vice Chairman), and several independent directors: Dr. Eric Ende, Ms. Natasha Giordano, Mr. James Scibetta, and Dr. Matthew Wikler. This team combines executive leadership with independent oversight for strategic governance.

Matinas BioPharma Holdings, Inc. is a micro-cap biopharmaceutical company focused on developing novel pharmaceutical products. As of March 2025, it reported a net loss of $2 million and has a market cap of $4.65 million.

As of Jun 18, Matinas BioPharma Holdings, Inc. has a market capitalization of 4.65 million, with net sales of 0.00 million and a net profit of -20.09 million over the latest four quarters. The company reported shareholder's funds of 7.59 million and total assets of 12.64 million as of Dec 24.